The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

The following is a summary of “Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal transition and promote bladder cancer progression,” published in the April 2025 issue of BMC ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

Hundreds of patients are expected to benefit from the recommendation by the National Institute of Health and Care Excellence.

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

New research suggests that an “often-overlooked” parasitic infection, already linked to bladder cancer, may also raise the risk of cervical cancer.

A groundbreaking targeted treatment for the most common type of bladder cancer has been approved for use by the NHS, offering ...